Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151607-DP in Upper Limb Essential Tremor
NCT07673107Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Countries
- 2
01
Overview
A Phase 2 trial of gemibotulinumtoxinA in essential tremor (ET), sponsored by AbbVie Inc.. Started Jun 2026; status: recruiting.
02
Drugs
gemibotulinumtoxinA
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT07673107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673107.